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Background: The Head and Neck Cancer Working Group of Swiss Group for Clinical
Cancer Research (SAKK) has investigated the level of consensus (LOC) and discrepancy
in everyday practice of diagnosis and treatment in head and neck cancer.
Materials and Methods: An online survey was iteratively generated with 10 Swiss
university and teaching hospitals. LOC below 50% was defined as no agreement, while
higher LOC were arbitrarily categorized as low (51–74%), moderate (75–84%), and
high (≥85%).
Results: Any LOC was achieved in 62% of topics (n = 60). High, moderate and low
LOC were found in 18, 20, and 23%, respectively. Regarding Head and Neck Surgery,
Radiation Oncology, Medical Oncology, and biomarkers, LOC was achieved in 50, 57,
83, and 43%, respectively.
Conclusions: Consensus on clinical topics is rather low for surgeons and
radiation oncologists. The questions discussed might highlight discrepancies, stimulate
standardization of practice, and prioritize topics for future clinical research.
Keywords: consensus, head and neck cancer, patterns of care, practice patterns, survey
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INTRODUCTION
The cause of heterogeneity in the practice of diagnosis and
treatment of head and neck squamous cell carcinoma (HNSCC)
can be associated with multiple factors: differences in health
care policies, financial and logistic factors, variations in tradition
and medical culture between geographical areas, institutions,
or even among physicians working in the same hospital. This
heterogeneity in patterns of care is expected to be inversely
correlated with the level of evidence on a given topic.
Literature on various aspects of management of HNSCC
were previously published. Such reports usually focused on an
anatomical site of the head and neck area (1, 2), a specific
treatment approach in a clinical discipline (3–6), diagnostic
modalities and strategies for diagnosis (7) and follow-up (8).
Most of these survey-based studies were performed among
institutions sharing the same geography or language.
The Head and Neck Cancer Working Group of Swiss Group
for Clinical Cancer Research (SAKK) is a multidisciplinary
collective of head and neck cancer specialists from many Swiss
institutions meeting in regular intervals and collaborating in
various projects. Due to the lack of a similar comprehensive work
published so far, the group decided to perform a survey covering a
broad spectrum of controversial topics concerning the diagnosis
and the treatment of HNSCC among its member institutions.
This survey was designed to discuss current diagnostic
and treatment strategies for HNSCC of all localizations
undergoing within the Head and Neck Cancer Working
Group of SAKK (multidisciplinary and multi-institutional)
and to find out probable differences between the
participating members/institutions in a pattern of
care study.
MATERIALS AND METHODS
In order to investigate the consensus and heterogeneity in the
various aspects of diagnosis and treatment of HNSCC, an online
survey via Surveymonkey R© (San Mateo, CA) was generated and
used by taking the following steps.
1) A steering committee of two head and neck surgeons, one
medical oncologist and three radiation oncologists (P-M. P.
serving as a consultant for methodology and technical issues)
was founded to generate a questionnaire draft, evaluate the
answers and writing the final manuscript.
2) Centers in which every patient diagnosed with a HNSCC
is presented and discussed on a multidisciplinary tumor
board on a regular basis, were defined and contacted through
the member list of SAKK by email or phone and a local
coordinator for each center was assigned. A rather balanced
distribution of the specialists defined as local coordinators
from the disciplines of head and neck surgery, medical
oncology, and radiation oncology was encouraged. The
responsibility of the local coordinator (e.g., the medical
oncologist in a center) was to address the part of the
questionnaire related to their specialty (medical oncology)
and organize the information flow with her/his institutional
colleagues from the remaining two major disciplines (head
and neck surgery and radiation oncology). As a trade-
off between being completely inclusive and realistically
conducting the survey, specialists of the above-mentioned
three disciplines were asked also to address the questions
about imaging, pathology, and maxillo-facial surgery on
behalf of the corresponding specialists of these disciplines.
3) The preliminary draft of the questionnaire was generated by
the steering committee and sent to each local coordinator.
Four categories were generated: head and neck surgery,
radiation oncology, medical oncology, and biomarkers. Each
center was asked to assign a numerical point for each
question, proportionally reflecting its level of importance
in the concerning category. Centers were also asked for
feedback for any unclear questions, to suggest modifications
and new questions.
4) After receiving feedbacks about the draft version, the
questionnaire was finalized for improved wording as
suggested and based on two criteria: (1) if a new question
was suggested from more than one center in same or similar
context, it was added to the final version, and (2) each
category was limited with a maximal number of 20 questions,
and questions with lower cumulative points were eliminated.
5) The final version (Supplementary Material) was transformed
into an online survey and each center was asked to fill
out the questionnaire. Each center is represented by a local
coordinator as listed in the co-authors and their affiliations.
6) Answers were evaluated and discussed by the steering
committee. Similar topics were grouped together.
7) For each question, an agreement per center is counted as 10
and a disagreement as 0, giving a minimal score of 0 and a
maximal score of 100. Missing answers are indicated in the
corresponding denominators. Level of consensus (LOC) was
calculated by summing all center’s answers and categorized
as lack of LOC (0–50%), low LOC (51–74%), moderate (75–
84%), and high (≥85%).
RESULTS AND DISCUSSION
Ten centers participated in the survey. The survey was completed
on 13 September 2017. Possible practice changes which may have
occurred after this date were not reflected in this manuscript.
Union for International Cancer Control (UICC) 7th edition (9)
was used for discussions related to staging.
Some LOC was achieved in 62% of all topics of interest, while
no LOC was found in 38% of questions. High, moderate and low
LOC were 18, 20, and 23%, respectively. LOC in each section is
summarized in Table 1.
Following section provides the results for the items
concerning head and neck surgery discipline, each followed
by a short discussion if deemed relevant.
Head and Neck Surgery
Diagnostic Measures
â Routine use of diagnostic panendoscopy: high LOC (100%).
During the diagnosis and baseline workup, all (10/10) centers
routinely performed an endoscopy of the upper aerodigestive
tract under general anesthesia to detect synchronous secondary
Frontiers in Oncology | www.frontiersin.org 2 October 2019 | Volume 9 | Article 1125
Dulguerov et al. Controversies in Head and Neck Cancer
TABLE 1 | Level of consensus in each section.
Section Overall
(>50%)
Low
(51–74%)
Moderate
(75–84%)
High
(85–100%)
Head and neck surgery 50% 21% 0% 29%
Radiation oncology 57% 14% 33% 10%
Medical oncology 83% 39% 22% 22%
Biomarkers 43% 14% 14% 14%
malignancies. In one center, panendoscopy was not part of
the routine workup for patients without history of tobacco or
alcohol abuse.
The incidence of synchronous HNSCC around 5–6% (10, 11) is
considered high enough to require a diagnostic panendoscopy.
Usually, the second primary is of small size and thus curable.
Hence, the diagnosis of synchronous lesions usually alters the
therapeutic approach. Since 18F-fluorodeoxyglucose positron
emission tomography combined with computerized tomography
(18FDG-PET/CT) is often performed during the evaluation or
treatment planning, some have suggested that a 18FDG-PET/CT
scan could replace endoscopy (12). However, 18FDG-PET/CT
will not detect small superficial lesions which are main focus
of endoscopy (13, 14) and Swiss centers are unanimous in
using panendoscopy during the initial evaluation. However,
this practice can be questioned in non-smoker patients who
are diagnosed with a Human Papillomavirus (HPV)-associated
oropharyngeal squamous cell carcinoma (OPSCC) due to the
decreased rates of secondary malignancies (15–17).
â Routine diagnostic use of 18FDG-PET/CT to address loco-
regional extension: low LOC (60%).
â Routine diagnostic use of 18FDG-PET/CT to address distant
metastases or second primary tumors is preferred: high
LOC (100%).
The use of 18FDG-PET/CT for the purpose of determining the
extent of the loco-regional disease is being used in 6/10 centers.
In all centers 18FDG-PET/CT was undergone to detect/rule out
distant metastases or locate the primary tumor in the staging of a
clinical carcinoma of unknown primary (CUP).
There is no high-level evidence for or against the value of the
18FDG-PET/CT for an accurate estimation of the extent of the
disease, especially for the primary site. Since the gold standard
is the assessment of the surgical specimen, a correlation between
parameters such as dimensions, volume, depth, or involvement
of critical structures obtained radiologically and pathologically is
sought (18). Because of the distortions and shrinkage of surgical
specimen, few studies have been undertaken especially for 18FDG-
PET/CT. The available data for 18FDG-PET/CT is restricted to
laryngo-hypopharyngeal primaries and is based on a total of 19
patients (19, 20): tumor volume estimation seems accurate but
the superficial extension was inaccurate. While surgeons possibly
have the direct estimation of the superficial spread to complement
the radiologic findings, the widespread use of 18FDG-PET/CT on
target volume delineation for radiation could be questioned.
In some series, the sensitivity of 18FDG-PET/CT is shown
to be superior to CT and MRI for the identification of occult
neck lymph node metastases (21). However, the sensibility of all
techniques remains low in this setting, around 60% (22). 18FDG-
PET/CT seems to accurately estimate volumes of metastatic neck
lymph nodes (23), but adds marginal value to the information
obtained from standard imaging modalities, such as CT or MRI
in clinically N+ patients (24).
The role of 18FDG-PET/CT for the diagnosis of distant
metastases seems more straightforward, but because of the
low incidence of distant metastases from HNSCC at initial
presentation, it should be restricted to advanced N stages.
Furthermore, 18FDG-PET/CT is useful to diagnose synchronous
cancers such as lung or abdominal primaries, although the
superiority over chest CT has not been demonstrated (25).
For unknown primaries, the added diagnostic value of 18FDG-
PET/CT in the pre-HPV era was about 20% (26), while small
recent studies and imaging modalities might increase the yield to
50% (27).
Management of the Neck
â Use of sentinel lymph node biopsy (SLNB) in cN0 oral cavity
tumors: no consensus.
In cN0 oral cavity primaries, SLNB is performed only in
4/10 centers. The reasons not to perform the technique were
not queried.
The only randomized prospective study in cN0 oral cavity
management concluded that neck exploration during the initial
treatment resulted in better overall and disease-free survival than
observation followed by therapeutic neck dissection for nodal
recurrences. This study validated elective neck dissection, not
sentinel neck biopsy (28).
Proponents of SLNB in cN0 neck stress that many patients
(70%) will have a non-metastatic neck and therefore will be
overtreated by a surgery associated with a substantial morbidity.
If this line of arguments is followed, omitting SLNB in
oral cavity primaries could be seen as suboptimal surgical
oncology management.
The arguments against a SLNB approach when comparing it
to the traditional elective neck dissection include: (1) oncologic
inferiority, (2) unavailability or unreliability of frozen sections in
SLNB, (3) need of a second procedure in case of SLNB positivity,
(4) technical challenges and learning curve of the procedure,
(5) lack of conviction in the difference in morbidity between
the two approaches. The arguments for a SLNB include (1) less
invasive approach, (2) second stage completion neck dissection
only necessary in the minority of patients (25–30%), (3) selective
detection of the lymph nodes of highest risk to harbor metastatic
disease, (4) the pathologic workup of sentinel lymph nodes allows
for the detection of small metastatic disease such as isolated
tumor cells and micrometastases rather than macrometastases
only leading to a more accurate staging of the neck.
Because of the pathology processing, most pathologists are
reluctant to recommend frozen sections in a sentinel lymph
node approach. Since frozen section of a sentinel lymph node
usually consists in the examination of a single section, several
studies have found this technique is suboptimal or unreliable (29).
The unavailability of frozen sections or their lack of reliability
makes most centers use SLNB during one procedure, with a
subsequent neck dissection performed during a second operation.
If the initial panendoscopy is performed as a separate procedure,
this could make three general anesthesia for the treatment of a
T1 carcinoma.
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An elective neck dissection approach with frozen sections of
lymph nodes appearing suspicious during the procedure allows
for definitive neck management by completing the dissection
in the same surgical setting (therapeutic neck dissection) when
frozen section yields occult nodal metastasis.
The advocates of SLNB consider that 20–50 cases are necessary
during the learning phase of the technique, while most head and
neck surgeons dealing with cancer are quite proficient in elective
neck dissection. Other problems include the necessity of a nuclear
medicine exam, the necessity of the surgeon to be available for the
intraoral injection, the pain associated with the awake intraoral
injection, and difficulties of scheduling an operating theater with
a specific delay after the injection.
Beyond difficulties accepting new techniques, if the morbidity
associated with elective supra-omohyoid selective neck dissection
was considerable, oncologic head and neck surgeons would have
had adopted SLNB readily. However, around half of the centers
probably consider that convincing data of such superiority is
lacking (30, 31). Probably the main advantage of SLNB is the
more thorough pathologic examination of the lymph nodes most
at risk, but the exact oncologic significance of micro-metastasis in
HNSCC remains to be determined.
Whether, an N0 neck is treated by elective neck dissection or
SLNB, follow-up is essential, especially for necks not requiring
adjuvant therapy. Radiologic surveillance could be accomplished
by various modalities (CT, MRI, and US) with US-FNAC being
the most accurate and cost-effective (32, 33). This neck follow-
up policy is valid in other situations where the primary is
treated surgically and the neck not treated, for example an early
laryngeal primary.
â Standard use of any up-front neck dissection strategy for
advanced neck stages: no consensus.
In the chemoradiotherapy (CRT) setting, 4/8 centers pursue a
systematic elective neck dissection strategy. Three of those 4
perform an up-front neck dissection in case of a cN2/3 disease,
whereas a planned neck dissection 8–12 weeks after CRT is
preferred in the fourth center.
CRT has become the preferred strategy for pharyngeal (34) and
laryngeal (35) primaries in some centers. Advanced stage disease
is often associated with bulky (N3) or multiple (N2b/c, N3) neck
lymph node metastasis and the optimal strategy to treat these
metastatic neck diseases remains controversial. Possible strategies
include: (1) up-front neck dissection before CRT; (2) planned
neck dissection after CRT; or (3) radiologic surveillance. Several
Swiss centers have pursued the up-front neck dissection since
the 1990’s (36, 37) and have not found convincing arguments to
change their strategy (38). Until recently, the debate has been
centered on whether a planned neck dissection after CRT is
necessary and whether a post-treatment 18FDG-PET/CT scan can
be used to select patients needing surgery. This has been settled
in a randomized controlled trial showing that a post-treatment
18FDG-PET/CT scan would safely identify patients not requiring
neck dissection after CRT (39). The question of up-front neck
dissection vs. post-CRT treatment is the subject of an ongoing
prospective multicenter study in Switzerland (NCT02918955).
â Systematic division and reporting of lymph node levels after a
neck dissection: no consensus.
When performing a neck dissection, 4/8 centers systematically
mark the lymph node stations before sending the material
to pathology.
Whether neck dissection is therapeutic (cN+) or elective (cN0),
one of its main purposes is to determine which patients are
candidates for adjuvant therapy (40). Since neck irradiation is
no longer performed by lateral opposed fields but by intensity
modulated radiotherapy optimized via inverse planning, precise
knowledge of the metastatic groups is crucial to the radiation
oncologist. The American Head &Neck Society recommends that
neck contents should be divided into levels and sublevels by the
surgeon in the operating room immediately after the specimen is
removed, each level being placed into a separate container and
labeled appropriately (41, 42). One possible exception to these
guidelines is obtaining negative margins on bulky and obviously
metastatic nodes, which might require keeping two or three
adjacent levels together. Even a pathologist specialized in HNSCC
has trouble deciding on the limits of individual groups without the
orienting presence of the hyoid bone and of the cricoid cartilage,
especially on a neck dissection specimen fixed in formalin.
â Impact of depth of tongue infiltration on the decision to
perform a neck dissection: no consensus.
For the carcinoma of the lateral side of the tongue, the depth
of invasion does not influence the decision to perform a neck
dissection in two centers. In five centers, 2–8mm depth of
invasion (mean and median 4mm) would change the treatment
strategy. Three centers did not provide any answer.
Convincing data on the relationship between tumor thickness and
prognosis in oral cavity squamous cell carcinoma date back to the
1980’s (43). Recently and after this questionnaire was completed,
depth of invasion was incorporated in the T staging system for
oral cavity carcinoma and validated in recent studies (44, 45).
The treatment strategy, especially for neck management, should
be more aggressive with depth of invasion >4mm (44, 46).
Management of Bone and Peri-Neural Invasion
â Adequate resection margin of mandible in case of bone
invasion: no consensus.
In case the CT and/or MRI suggest a 2 cm long cortical defect on
the body of the mandible with a 5mm depth of invasion without
any enhancement of the mandibular nerve, resection margins of
1, 2, and 3 centimeters would be used in 3, 2, and 1 centers,
respectively. Four centers did not provide any answer.
Three decades ago, Slootweg and Muller (47) described two
patterns of mandibular invasion: an “erosive pattern” carrying
a good prognosis and associated with direct bone infiltration
by the carcinoma, on a broad front, without infiltration of the
periodontal ligament and of the inferior alveolar nerve. The
“infiltrative pattern” carries a worse prognosis and histologically
exhibits an aggressive invasion ofmandibular cancellousmarrow,
periodontal ligament, as well as a frequent perineural invasion
of the inferior alveolar nerve. Subsequent series (48, 49) have
confirmed two- to three-fold higher recurrence rates and
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approximately halved survival in the infiltrative pattern of
invasion. Furthermore, because cortical bone invasion does not
carry a poor prognosis, it has been suggested that to stage it as
T3 (50).
The literature rarely speaks of “erosive” and “infiltrative”
pattern but often refers to cortical vs. marrow infiltration.
Preoperative performance for mandibular marrow invasion of
MRI carries a high sensitivity (95–100%) but a lower specificity
(60–70%) (51, 52).
According to the Dutch Guidelines Database (53), in the
erosive pattern a bony margin of 1 cm is sufficient, while the
infiltrative pattern requires bony margins of 1.5 cm and invasion
within the canal of the mandibular nerve 2 cm. While these
recommendations are cited in the literature, their exact scientific
foundation is unclear.
â The indication to perform a mandibulectomy in case of
mandibular nerve invasion: no consensus.
In case of an oral cavity tumor where the MRI suggests an
enhancement of the mandibular nerve and the CT shows
no erosion of the mandible, 2/8 centers would perform a
mandibulectomy, whereas the rest would not or decide based on
the intraoperative assessment.
Involvement of the inferior alveolar nerve is associated with a
worse prognosis and requires more extensive resection (54). The
question thus addresses the possibility of assessing perineural
spread in mandibles with an intact bony cortex. Techniques
derived from MR neurography using special sequences, such
as 3D double-echo steady-state with water excitation have been
shown to have high sensitivity (95–100%) for detection perineural
spread (55, 56). While the radiological results have been
pathologically validated for HNSCC in general, no publication has
specifically targeted the inferior alveolar nerve.
Optimal Resection Margins
â Adequate resection margin should be 5mm in T1-2 oral cavity
tumors: high LOC (89%).
In a T1-2 oral cavity tumor, the adequate resection margin was
defined as 5mm in 8 centers. For one center, it was defined as
10mm. One center did not provide an answer.
A “sufficient” pathological margin implies a low risk for tumor
recurrence and possibly makes adjuvant treatment redundant.
However, this issue for oral squamous cell carcinoma is still a
subject to debate. Combined analysis (57) of the EORTC 22931
(58) and the RTOG 9501 (59) trials concluded that the adverse
prognostic factors requiring adjuvant CRT following surgical
resection included extracapsular extension (ECE) of metastatic
lymph nodes and positive margins. Somewhat provocative results
were published from the Toronto group evaluating oral cavity
pN0 patients with margins smaller than 5mm, treated only
surgically: negative margins of 1–5mm were not associated with
inferior local control; while tumor thickness, perineural invasion,
and pattern of invasion were predictive of local recurrence
(60). The data are in agreement with other studies, establishing
pathological scores for resected oral squamous cell carcinoma
(61). A review of the literature on the subject seems to confirm
that most studies consider 5mm as a negative margin (60),
following the Guideline of the UK Royal College of Pathologists:
>5mm clear, 1–5mm close, and <1mm positive margin (62).
This discussion pertains to margins assessed by the pathologist
and given about 50% shrinkage of the specimen (63), resection
should start about 10mm from the tumor edge.
Treatment of Laryngo-Hypopharyngeal Primaries
â The status of vocal cord mobility is a key criterion for primary
treatment decision: low LOC (63%).
In glottic larynx cancer, vocal cord mobility affects the treatment
decision in 5/8 centers.
The presence of vocal cord mobility indicates that there is
probably an infiltration of the vocal muscle or in rare cases of the
crico-arytenoid joint. This is a well-recognized adverse prognostic
factor and has been incorporated in the TNM classification for
glottic cancer since 1988: an otherwise T1 carcinoma would
become a T2 in case of hypomobility, and T3 for complete
immobility (64).
The main implication of vocal cord mobility impairment is
that the tumor is much bulkier (65) and has extended laterally.
Because of this, endoscopic surgery will be more extensive
(66) and thus result in more important functional voice and
swallowing impairment. Furthermore, especially for T3 cases, the
resection might not be possible endoscopically and open partial
laryngectomy might become the procedure of choice (67). Even if
radiation is the chosen treatment modality, impaired vocal cord
mobility carries the main adverse prognostic factor in T2 glottic
cancers (68) and is associated with suboptimal cure rates (69).
Why vocal cord mobility does not bring a consensus higher
than 63% is difficult to understand. Since vocal cord mobility
clearly influences the surgical approach, only possibility is that
in some centers, all low stage (T1–T2) carcinoma are treated
with radiation therapy and surgeons do not see the mobility as
a decisive factor.
â Radiologic imaging is reliable to assess laryngeal cartilage
invasion: high LOC (86%).
Radiologic imaging modalities are considered to be reliable to
assess cartilage invasion of larynx cancer in 6/7 centers.
Cartilage invasion has a major impact in the optimal management
of laryngeal cancer (see the following question). Cartilage
invasion cannot be assessed clinically and therefore, a reliable
diagnostic test is essential. The main options are CT and MRI.
It should be kept in mind that the gold standard of evaluating
performance of radiological exams is definitive pathology and
thus studies evaluating CT and MRI only include patients that
underwent surgery which is often total laryngectomy. Thus,
compared to the general population of patients with laryngeal
cancer, cartilage invasion is probably over-represented, and this
bias probably leads to an overestimated positive predictive value
(PPV) and to an underestimated negative predictive value (NPV)
for the diagnostic modality under investigation.
A recent meta-analysis of CT shows a prevalence of cartilage
invasion between 19 and 27%, a PPV ranging between 44 and
80%, and relatively high NPVs ranging between 85 and 100% (70).
In other words, false positive CT scans are frequent, while false
negative CT scans infrequent and according to the authors, false
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negative cases stem from minor cartilage invasion, which might
not be a contra-indication to conservative treatments, being CRT
or partial laryngectomies. Similar results were found in classical
studies on the subject (71). However, the performance of CT
for extralaryngeal spread is insufficient with NPVs of only 71%
(72), making CT not reliable for selecting patients for organ
preservation strategies.
MRI can improve the NPVs of CT above 95% in experienced
hands (18) and because of its excellent soft tissue evaluation, is
the preferred evaluation method for extralaryngeal spread (73).
The PPVs are however not better than CT.
â To prioritize larynx preservation strategies in cT4a laryngeal
primaries or not: no consensus.
The first choice of treatment in cT4a laryngeal primaries is
always to pursue a larynx preservation strategy in one center.
Four centers prefer CRT only if the cartilage is not destructed.
Other five centers always prefer total laryngectomy followed by
adjuvant treatment.
T4a laryngeal carcinoma by definition invades the cartilaginous
framework of the larynx and remains best treated by a
multimodality regimen, starting with total laryngectomy (74).
This has been reemphasized in the recently updated guidelines
from the American Society of Clinical Oncology: for “extensive T3
or large T4a lesions and/or poor pretreatment laryngeal function,
better survival rates and quality of life may be achieved with total
laryngectomy rather than with organ-preservation approaches
and may be the preferred treatment strategy” (74).
The debate originated after the VA trial (75) demonstrating
that some T4a larynx tumors could be preserved by a CRT
protocol. However, in this study, 56% of T4a patients underwent
total laryngectomy, especially in glottic primaries with cartilage
invasion. Because of that, this population was specifically
excluded from the RTOG 91–11 trial (76). This trial was based
on the 5th UICC classification of 1992, and the change in the T3–
T4 larynx T-staging introduced in the 6th UICC edition added to
the confusion. Small inner cortex erosion was classified as T4a in
the 5th edition and as T3 in the 6th edition. It is probably safe to
say that present day T4 patients were not included in the RTOG
91–11 trial.
As discussed in detail in the guideline of the American Society
of Clinical Oncology (74), several high-quality retrospectives
studies (77–82) support the better survival of T4a laryngeal
cancer patients treated with total laryngectomy, rather than
CRT protocols.
â The preferred treatment of cT1/2 hypopharyngeal cancer is
non-surgical: low LOC (60%).
A cT1/2 hypopharyngeal primary is never treated surgically in
6/10 centers.
Hypopharyngeal primaries are associated with low survival (5-
year overall survival about 30%) that has barely improved over
the years (83). Radiotherapy or CRT are often considered as
the standard treatment for hypopharyngeal primaries (84, 85),
whereas surgical series with voice preservation are not new
(86). No randomized trial has addressed early hypopharyngeal
carcinoma. For early T1–T2 primaries, small series with surgical
resection, often endoscopic and without adjuvant irradiation,
provide encouraging results (Table 2).
TABLE 2 | Results of early stage hypopharynx cancer patients in selected surgical
series.
References Stage I (n) Stage I-
5yLRC
Stage II (n) Stage II-
5yLRC
Laccourreye (87) 34 95%
Eckel (88) 10 75% 22 75%
Steiner (89) 10 95% 23 95%
Kutter (90) 24 90% 28 90%
Martin (91) 7 73% 19 59%
Karatzanis (92) 45 90% 74 83%
5yLRC: 5-years loco-regional control; n: number.
CONCLUSION
The findings of our survey indicate a low LOC among
head and neck oncologists working in academic and
multidisciplinary setting in 10 Swiss institutions. Regarding
the results and the discussion concerning the specialties
other than head and neck surgery, the reader is advised to
read the corresponding parts of this article. The highest
LOC was achieved among medical oncologists, whereas the
lowest was observed among head and neck surgeons. On
the other hand, this level of disagreement may also depend
on the topics chosen for the survey, and not necessarily the
heterogeneity within the disciplines. It is also interesting to
witness a low LOC regarding topics, where a high level of
evidence actually does exist, and vice versa. This article is
expected to serve the head and neck oncologists to be aware
of their discrepancies and to stimulate discussion toward
standardization of practice and prioritize topics of future
clinical research.
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